In randomized clinical trials, for example, on cancer patients, it is not uncommon that patients may voluntarily initiate a secondary treatment postrandomization, which needs to be properly adjusted for in estimating the "true" effects of randomized treatments. As an alternative to the approach based on a marginal structural Cox model (MSCM) in Zhang and Wang [(2012). Estimating treatment effects from a randomized trial in the presence of a secondary treatment. Biostatistics 13, 625-636], we propose methods that treat the time to start a secondary treatment as a dependent censoring process, which is handled separately from the usual censoring such as the loss to follow-up. Two estimators are proposed, both based on the idea of inversely weighting by the probability of having not started a secondary treatment yet. The second estimator focuses on improving efficiency of inference by a robust covariate-adjustment that does not require any additional assumptions. The proposed methods are evaluated and compared with the MSCMbased method in terms of bias and variance tradeoff using simulations and application to a cancer clinical trial.
INTRODUCTION
In randomized clinical trials, for example, on cancer patients, it is not uncommon that patients may initiate a secondary treatment postrandomization at the discretion of the patients or their caregivers. Unlike non-compliance which violates a study protocol, whether or not and when to start a secondary treatment are usually not specified in a study protocol and consequently effort will not be made to minimize its occurrence, leading to a possibly high percentage of patients receiving a secondary treatment that cannot be appropriately ignored in analysis. For example, in a randomized phase III clinical trial comparing Cisplatin (control) and a Pemetrexed/Cisplatin combination in patients with malignant pleural mesothelioma in terms of survival times (Vogelzang and others, 2003) , it was found that more than 40% of patients 492 M. ZHANG AND Y. WANG received a second-line chemotherapy after discontinuing from the study treatment. Since in the control arm there is a higher percentage of secondary treatments (47% vs. 37%) and patients started secondary treatments earlier (0.7 vs. 3.3 months since the dicontinuation of the first treatment), such imbalance may lead to an attenuated estimate of the "true" effect of the combination treatment using usual methods where secondary treatments are not properly adjusted for. As opposed to the intent-to-treat (ITT) perspective, the trial was studied in Zhang and Wang (2012) with the objective of estimating the causal effects of the randomized treatments in terms of the hazard ratio under the hypothetical situation if no patients were to receive a secondary treatment. The objective of this article is the same as that in Zhang and Wang (2012) , but we propose an alternative and more robust method to adjust for secondary treatments.
Although our target is the randomized treatments, as noted in Zhang and Wang (2012) , the usual methods do not yield valid causal inference because the receipt of a secondary treatment is observational and the usual methods do not take proper account of baseline and time-dependent confounders that predict both secondary treatments and survival. Zhang and Wang (2012) adjusted for a secondary treatment by modeling its effect using the marginal structural Cox model (MSCM; Hernán and others, 2001; Robins and others, 2000; Kim and others, 2005) and, using the principle of Zhang and others (2008) , proposed an estimation method that improves the efficiency over the inverse probability of treatment-weighted method. The MSCM is a time-dependent Cox model on potential lifetimes, which assumes that the timedependent secondary treatment has a multiplicative effect on hazard as well as the randomized study treatments. This is a strong assumption, which may not be satisfied for a particular data set, and as we demonstrate later, violation of this assumption may lead to unignorable bias in estimating the effects of the study treatments. Alternatively in this article, we propose to account for secondary treatments by viewing it as a dependent censoring process and, as the mechanism of the dependent censoring induced by a secondary treatment is likely different from that of the usual censoring such as loss to follow-up, the two types of censoring are not combined and handled separately. Two methods based on the idea of inverse probability of censoring weighting (IPCW; Robins and Rotnitzky, 1992; Robins and Finkelstein, 2000; Schaubel and Wei, 2011) are proposed to adjust for the induced dependent censoring. As information on patients' survival postsecondary treatment will be lost if survival times are censored by the secondary treatment, methods based on this idea are expected to be less efficient than the MSCM-based methods and thus improving efficiency is especially desirable. The second method focuses on improving efficiency through a robust covariate adjustment (Zhang and others, 2008; Koch and others, 1998) . Since our methods do not model the effect of the secondary treatment, an advantage is that they are more robust than the MSCM-based methods. We will evaluate the tradeoff of bias and variance between the two approaches by simulations and application to the motivating cancer trial.
NOTATION AND ASSUMPTIONS
Consider a randomized clinical trial with n subjects randomly assigned to treatment Z = 0 or 1. We denote the survival time by T , which is subject to censoring, C, including, for example, loss to follow-up or administrative censoring due to the end of a study. The observed time for each subject is denoted by U = min(T, C) with the corresponding non-censoring indicator defined as = I (T C). Standard methods for inferring treatment effects in a randomized study are usually based on data on (Z , U, ).
In the setting that we consider in this article, subjects or their caregivers may choose to initiate a secondary treatment after discontinuation from the assigned study treatment. Let P denote the potential time to start a secondary treatment and U P = min(P, U ) be the minimum of observed time to secondary treatment if initiated, death or censoring. Correspondingly, the indicator for observing a secondary treatment is P = I (P U ). As secondary treatments are usually not randomized or under the control of investigators, patients who started a secondary treatment may differ from those who did not in
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493 characteristics measured at baseline and after randomization. We denote the vector of observed baseline covariates by X and time-dependent covariates at t by V (t). In summary, the observed data are
. . , n, assumed to be independent and identically distributed (i.i.d.) across i.
The quantity of interest is the marginal (unconditional) hazard ratio of Z = 1 relative to Z = 0 under the ideal situation where no one in the study initiated a secondary treatment. Therefore, we target the same quantity as in the primary analysis in an ideal trial where indeed secondary treatments do not exist. Under the ideal situation, the standard method is to fit a Cox model including the treatment indicator Z only. As our data deviate from the ideal trial, some sort of adjustment for the secondary treatment is necessary. In the following, we first describe how the treatment effect of Z in the presence of a secondary treatment can be conceptualized using the framework of potential outcomes.
In an ideal trial where secondary treatments do not exist, there is a potential survival time corresponding to each subject, which we denote by T * , and a potential time to censoring C * . In reality some subjects started a secondary treatment, but conceptually it is still T * that is of interest for our objective and thus we can still define such a counterfactual survival time T * of a subject, if possibly contrary to fact, s/he never started a secondary treatment. It is easy to see that for a subject who did not initiate a secondary treatment T * = T , but T * = T if the subject started a secondary treatment in reality since the secondary treatment is expected to affect the survival experience of a subject; similarly, C * may not equal C. To put it in another way, even in the absence of other censoring, T * may still be censored due to the initiation of a secondary treatment, although T can be observed. Therefore, considering T * as the outcome, T * is possibly not observed due to two reasons; i.e. T * may be censored when C * < T * or due to the secondary treatment if P < T * . Viewing both C * and P as censoring and T * as the outcome, as typically in survival analysis, one can then define the observed, possibly censored survival time as the minimum of the potential survival time and the combined censoring, i.e. min(T * , C * , P), and it is easy to see that min(T * , C * , P) = U P . Correspondingly, the non-censoring indicator for T * is defined as † = I (T * = U P ), which equals I (T = U P ) and is observed for all subjects. Note, previously, we defined an indicator for secondary treatments, P , which equals 1 when U P = P and 0 otherwise; similarly, we define an indicator for censoring with
As discussed above, viewing T * as the outcome of interest, for each subject, one observes a time and the corresponding non-censoring indicator, namely, U P and † , respectively. However, U P and † cannot directly be used to estimate the treatment effects using the standard methods. This is because T * is partially censored by the time to initiate a secondary treatment, which may possibly depend on patients' baseline and time-dependent characteristics that are also predictive of survival experience, e.g. tumor size measured periodically for cancer patients. However, the standard method by fitting a Cox model including only Z assumes that censoring is independent of survival given Z , which is clearly violated here. With respect to P, we make the following "no unmeasured confounders" assumption (Hernán and others, 2001) , written explicitly as
This assumption states that, conditional on past treatment and covariate history, the hazard of initiating a secondary treatment can be viewed as random and is independent of the potential survival and censoring times. In applications, if information used in making a decision on whether to start a secondary treatment, such as demographics, comorbidities, severity, etc., is captured in the data at hand, then this assumption is plausible. Potential lifetimes T * may also be censored by the usual type of censoring including loss to follow-up or administrative censoring due to the end of a study. We do not combine this type of censoring with the induced censoring by secondary treatments as we believe they are likely governed by different mechanisms. In a randomized trial where there were no secondary treatments, investigators are usually willing to assume that such censoring is independent of T * given Z , i.e. T * ⊥ ⊥ C * |Z . In the presence of secondary treatments, however, it is possible that the initiation of a secondary treatment may affect the future censoring time (i.e. C = C * ) and the observed C may be correlated with T * through their mutual correlation with P even after conditioning on Z . Nevertheless, we argue that such dependent censoring does not require special attention in our methods that are based on data on (U P , † ). To see this, for a subject who did not initiate a secondary treatment, censoring is not affected by the secondary treatment in the sense that C = C * and is independent of T * given Z ; for a subject who started a secondary treatment, its future censoring time C is not important to us since T * is censored by P, which occurs before the censoring. Therefore, one may make the following independent censoring assumption in the presence of a secondary treatment, written as
which is essentially the independent censoring assumption when secondary treatment does not exist. As investigators are usually much more concerned about the secondary treatment than censoring, following the usual practice in many randomized clinical trials, we will make the above independent censoring assumption unless stated otherwise; extension to a more general censoring assumption is discussed at the end of Section 3.
METHODS
In a trial without secondary treatments, the standard method for estimating the marginal hazard ratio of Z is fitting the following Cox model:
where λ * (t|Z ) is the hazard function of T * , given Z , λ * 0 (t) is an unspecified baseline hazard function and β is the marginal log hazard ratio. In the presence of a secondary treatment, one may view T * , the outcome of ultimate interest, as censored by both C * and P with C * being the independent censoring and P the dependent censoring. To account for dependent censoring induced by P, we propose to use the method of IPCW, which inversely weights the contribution of each subject at each risk set, particularly in our application, by the probability of having not started a secondary treatment yet. Specifically, we estimate β byβ, which is the solution to a weighted estimating equation, i.e.
, denoting the at-risk and death processes, respectively, and w i (t) is a weight function for subject i at t. The weight
is (informally) the probability of having not started a secondary treatment conditional on (Z i , X i , V i ) and κ P (t; Z i ) is a function of Z i used to stabilize the weights (Hernán and others, 2001) . A discussion on why κ P (t; Z i ) is only a function of Z i but not of X i and how it can be used to stabilize the weights is given in supplementary material available at Biostatistics online. Note that if w i (t) is set to 1, this corresponds to the usual partial maximum likelihood estimator of a Cox model; therefore, standard software for fitting Cox models can be used to solve (3.2) if a weighing option is allowed, for example, proc phreg in SAS.
The usual IPCW estimator would inversely weight by the probability of remaining uncensored, whereas our weight involves censoring by P only, even though two kinds of censoring exist. That weighting with respect to P only is sufficient is because we make the independent censoring assumption specified previously. It can be shown that the solution to (3.2) is asymptotically equivalent to the solution of the estimating equation whereZ (t; β) is substituted by its limit, and the latter estimating equation is a summation of i.i.d. terms, referred to as the estimating function. Under the independent censoring assumption, using techniques as in Zhang and others (2011) or Zhang and Schaubel (2011) , it can be shown that the estimating function is unbiased in the sense that its expectation is zero under the true β. Solutions to unbiased estimating equations are referred to as M-estimators and, according to the theory of M-estimators, are consistent and asymptotically normal (Stefanski and Boos, 2002) . Therefore, the solution to (3.2),β, consistently estimates β.
The weight function has to be estimated in practice. Time-dependent Cox models can be used to estimate
For example, one may fit a model for each treatment separately, i.e.
P is censored by both T * and C * , but by assumption (2.1) the coefficient γ j can be consistently estimated. In fitting the model, U P would be treated as the time and P as the non-censoring indicator. Then W P (t; 
t)} using obvious notation. We comment that the modeling for P is the same as that in Zhang and Wang (2012) , however, the weight function is different. To estimate κ P (t; Z i ), we may fit a Cox model for P including Z only and estimate κ P (t; Z i ) by the estimated conditional probability of having not started a secondary treatment yet, computed similarly as forŴ P (t; Z i , X i , V i ), or κ P (t; Z i ) can be estimated by the Kaplan-Meier curve of P for Z = 0, 1 separately. As IPCW-based estimators, correct specification of the model for P in estimating W P (t; Z i , X i , V i ) is required for consistent estimation of β; however, the model for P in estimating κ P (t; Z i ) is not required to be correct.
The key difference betweenβ and estimators based on an MSCM (Zhang and Wang, 2012 ) is thatβ uses information on patients' survival up to U P , whereas MSCM-based estimators use information up to U , including patients' survival experience after the initiation of a secondary treatment. Althoughβ is robust to misspecification of the marginal structural model, an unappealing feature ofβ is that it is less efficient. To remedy this, below we propose an improved estimator overβ in terms of efficiency and, asβ, it does not require modeling the effect of a secondary treatment. The improved estimator is developed by applying the general theory of Zhang and others (2008) . According to Zhang and others (2008) , for randomized trials, given an unbiased estimating equation, a class of unbiased estimating equations can be constructed by augmenting it with a function involving baseline covariates. This rich class include the original estimating equation as a special case and provide an opportunity to improve efficiency by identifying the best estimating equation in this class. Specifically forβ, rewriting (3.2) equivalently as 
where e(O i ; β) = {Z i −Z (t; β)}w i (t) dM i (t), π = P(Z = 1), and g(X i ) can be any function of X i . The unbiased estimating equation (3.2) is a member in this class with g(X i ) = 0. Estimating equations in class (3.3) are also unbiased since the augmentation term satisfies E{(
, where the second equality is due to Z ⊥ ⊥ X by randomization, which is the key to ensure unbiasedness. Therefore, solutions to (3.3) are a class of consistent and asymptotically normal estimators for β, according to the general results pertinent to M-estimators.
To identify the optimal estimator in class (3.3), we may directly minimize the asymptotic variance of solutions to (3.3). Using standard arguments for M-estimators, we derive that the asymptotic variance is
and similar algebra to that in Zhang and Wang (2012) 
, one needs to model and estimate the conditional expectation in practice. In modeling Zhang and others (2008) , solving the estimating equation (3.3) with the estimates of g opt (X i ) substituted will lead to the optimal estimator in the class of estimators in (3.3). However, if E{e(O; β)(Z − π)|X } is misspecified, which probably is inevitable in practice, the optimal efficiency gain is not realized and even loss of efficiency is possible when the model is terribly misspecified.
s) exp(β Z i )). If the model for E{e(O; β)(Z − π)|X } is correct, then according to
To guarantee the improvement in efficiency, following Zhang and others (2008) and Leon and others (2003) , we consider a subset of (3.3) with g(X i ) of the form g(X i ) = a T q(X i ), where q(X i ) is a vector of functions of X including an intercept term and possibly polynomial terms in X i , interaction terms, splines, and so on, and then to identify the best coefficient a. Noteβ corresponds to an estimating equation with a = 0, again belonging to the restricted class. Therefore, if we can identify the optimal a corresponding to an estimator in the class with the smallest asymptotic variance, it leads to a method that is guaranteed to be more efficient thanβ. Using argument similar to that in Zhang and Wang (2012) , we identify that the optimal a, say a opt , is {π(1 − π)} −1 b opt , where
and b opt can be consistently estimated byb = [ T q(X i ), using OLS, (ii) make predictionsb T q(X i ) for each subject, and (iii) solve the estimating equation (3.3) with g(X i ) = {π(1 −π)} −1bT q(X i ). We denote the resulting estimator byβ, which is covariate adjusted and improves efficiency overβ, and its variance can be consistently estimated by
. We comment that, as (3.3) is a class of unbiased estimating equations for any g(X i ), the consistency and asymptotic normality ofβ do not depend on the correct specification of E{e(O; β)(Z − π)|X } or q(X i ), and therefore the covariate-adjustment in obtainingβ is robust.
So far we have assumed that, given Z and that the secondary treatment has not initiated yet, the hazard of censoring is independent of potential lifetimes. The proposed methods can easily be extended to accommodate a more general assumption on censoring, i.e. the so-called "no unmeasured confounders" assumption for C * , given by
A natural extension is to use IPCW to further account for the dependent censoring by C * . Specifically, we modify w i (t) in the proposed methods by multiplying an additional term and the new weight function is
is the probability of remaining uncensored given all past treatment and covariates and κ C (t; Z i ), as κ P (t; Z i ), is a stabilization factor. In practice, W C (t; Z i , X i , V i ) and κ C (t; Z i ) can be modeled and estimated similarly as that for P except that we now treat U P as the time and C as the non-censoring indicator. We comment that, as we use U P instead of U as the outcome in the proposed methods for inference on model (3.1), we should inversely weight by the probability of remaining uncensored had there were no secondary treatments to account for the dependent censoring C * . Therefore, one should also use U P instead of U as the time outcome in fitting the models for C * .
SIMULATION STUDIES
Simulation studies are carried out to evaluate the finite sample performance of the proposed methods; each of the reported results is based on 1000 Monte Carlo data sets. We focus on comparing the proposed methods with the MSCM-based method (Zhang and Wang, 2012) in terms of efficiency and bias if the marginal structural model is wrong. We generated data the same way or similarly to those in Zhang and Wang (2012) . In the following, we set C = C * . Our first scenario is exactly the same as scenario 1, strong association case in Zhang and Wang (2012) , where C is dependent censoring; we refer readers to Zhang and Wang (2012) for details. In this scenario, potential lifetimes are generated according to an MSCM, which assumes both first and secondary treatments affect hazard multiplicatively and obviously the less restricted model (3.1) is also satisfied. We focus on situations where the more restrictive independent censoring assumption holds in the rest of the scenarios. Scenario 2 is the same as scenario 1 except that C is independent of all other variables with an exponential distribution with rate η, where η is chosen to yield 20% censoring. In scenarios 3-5, we generated T * such that the marginal structural model is incorrect but model (3.1) is still correct. Specifically in scenario 3, as in scenario 1, T * |Z follows model (3.1) with a baseline hazard function of an exponential (0.03), but instead of having a multiplicative effect on hazard, the secondary treatment has an additive effect on hazard, i.e. the hazard decreased by −0.0135 after the initiation of a secondary treatment. In scenario 4, T * |Z was generated according to (3.1) with a baseline hazard function of a lognormal (2.9, 1). Given T * , the effect of a secondary treatment on T follows a time-dependent accelerated failure time model (Cox and Oakes, 1984) , i.e. T * = T 0 exp{α I (P t} dt with α = −0.5, which leads to T = P + exp(−α)(T * − P). In scenario 5, T * was generated the same as in scenario 4, but we allow the effect of secondary treatment to differ by Z with α = −0.4 or −0.1 for Z = 0 or 1, respectively. All other variables including Z , baseline and time-dependent covariates and P are generated the same as in scenario 1, and C is generated as in scenario 2 but with a different η to yield 20% censoring. In all the scenarios, about 40% subjects started a secondary treatment and the true β is −0.4.
Results on scenarios 1-5 are reported in Table 1 , where β is estimated usingβ,β, and the MSCM-based method of Zhang and Wang (2012) with the stabilized weight. In particular, for scenario 1 where censoring is dependent, to obtainβ andβ, we use the proposed methods under the more general "no unmeasured confounders" assumption discussed at the end of Section 3. Under scenarios 1 and 2 where the MSCM is correct, all the three estimators are approximately unbiased and the 95% confidence intervals appear to achieve the nominal level. As expected, the covariate-adjusted estimatorβ is more efficient thanβ but is less efficient than the MSCM-based estimator. However, the MSCM-based estimator is not robust to misspecification of the marginal structural model, which is evident from results from scenarios 3-5. Under scenarios 3-5, where the effect of a secondary treatment on survival is misspecified, the MSCM-based method may lead to unignorable or even big bias and low coverage probability of confidence intervals, for example, in scenario 3. The proposed methods are more robust at the expense of being less efficient, as indicated by the relative efficiency compared with the MSCM-based method in column "RE1". The covariate-adjusted estimator,β, is more efficient thanβ, achieving more than 30% gain in efficiency relative toβ (see column "RE2") in the scenarios considered here. The degree of efficiency gain depends on the predictive power of baseline covariates; extensive simulations on this for different but similar problems have been reported in Zhang and others (2008) and also Zhang and Wang (2012) and therefore we do not pursue it in this article. Additional simulations on the impact of violation of assumption (2.1) and misspecification of the model for P are reported in supplementary material available at Biostatistics online. Naturally, the impact depends on the degree of violation and misspecification but, in general, the methods are not overly sensitive and usually are less biased than the naive methods.
APPLICATION
We apply the proposed methods to the trial introduced in the beginning; see Zhang and Wang (2012) for a detailed description of the trial. In the proposed methods, one needs to build a model for P as a function of Z , X, V (t) in calculating the weights. The model-building process for P and the final model are the same as those in Zhang and Wang (2012) and thus details are omitted. We estimated the treatment effect under both censoring assumptions. Under the independent assumption, the estimated log hazard ratios are −0.49 (SE: 0.155; HR = 0.61) and −0.58 (SE: 0.140; HR = 0.56), respectively, using the proposed estimators β andβ. We also carried out the analysis using the more general censoring assumption and we modeled censoring time using a time-dependent Cox model separately for each treatment group. The model selection criteria and the final selected covariates are the same as in Zhang and Wang (2012) , although we note that models are fitted differently since, in Zhang and Wang (2012) , U was used as the time variable but in this analysis U P was used instead. Several baseline and time-dependent variables are predictive of censoring. Under this censoring assumption, the estimated log hazard ratios are −0.44 (SE: 0.157; HR = 0.64) and −0.53 (SE: 0.142; HR = 0.59), respectively, usingβ andβ. For comparison, we list results from the ITT analysis, where one does not account for the secondary treatment or dependent censoring, and also from the MSCM-based method of Zhang and Wang (2012) . The ITT analysis yields an estimated log hazard ratio of −0.27 (SE: 0.115; HR: 0.77) and the MSCM-based method yields an estimate of −0.43 (SE: 0.140; HR 0.65). The proposed covariate-adjusted estimator,β, improves efficiency relative toβ by more than 20%. Loss of efficiency of the covariate-adjusted estimator relative to the MSCM-based method is only slight, at least in this particular application. It is not surprising that the ITT method gives the smallest estimated treatment effect as this method does not account for the imbalance in receipt of secondary treatments and the direction of imbalance would favor the control arm. In addition, the proposed methods, which make less assumptions than the MSCM-based method, yield a larger estimated treatment effect than the MSCMbased method.
DISCUSSION
As opposed to the MSCM-based approach, we proposed an alternative approach to adjust for secondary treatments in a randomized clinical trial. This approach treats the initiation of a secondary treatment as a dependent censoring process which censors the potential lifetime of a subject that would be realized if, possibly contrary to fact, he/she had not received a secondary treatment. The dependent censoring induced by secondary treatments and the usual censoring such as loss to follow-up are handled separately, instead of combined together. Two estimation methods are proposed, both based on the idea of inversely weighting by the probability of having not initiated a secondary treatment yet. The second method improves efficiency using a robust covariate adjustment that does not require any additional assumptions, for example, on the relationship of covariates and outcomes. This robustness is because this method takes advantage of the fact that baseline covariates are independent of the randomized treatment by design.
We compared the proposed approach with the MSCM-based method in terms of bias and variance tradeoff by simulations. As the MSCM-based method models, the effect of a secondary treatment, which enables it to use all available information on patients' survival even after patients started a secondary treatment, this method is more efficient but is less robust for the same reason since the effect may be modeled incorrectly. In contrast, the proposed approach is more robust because the effect of a secondary treatment on survival is left unspecified, but is less efficient. The proposed covariate-adjusted method is able to improve efficiency relative to the unadjusted method, but is still less efficient compared with the MSCM-based method of Zhang and Wang (2012) when the MSCM is the correct model. As simulations demonstrate, when the marginal structural model is misspecified, big bias is possible in the MSCM-based estimator; the proposed methods will have overall good performance in terms of bias. As no approach dominates the other in performance, which approach to choose depends on the particular application.
An augmentation term involving a function of (X, Z ) is used in obtainingβ to improve efficiency by exploiting the randomization. We note that this term does not correspond to the usual augmentation term in augmented inverse probability of missingness (or censoring) weighted estimating equations (AIPWE; (van der Laan and Robins, 2003; Tsiatis, 2006) ) that treat the induced censoring by secondary treatments
